James Larkin

List of Publications by Citations

151 papers	44,926 citations	52 h-index	172 g-index
172 ext. papers	56,071 ext. citations	13.8 avg, IF	6.85 L-index

#	Paper	IF	Citations
151	Improved survival with vemurafenib in melanoma with BRAF V600E mutation. *New England Journal of Medicine*, **2011**, 364, 2507-16	59.2	5851
150	Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. *New England Journal of Medicine*, **2012**, 366, 883-892	59.2	5559
149	Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. *New England Journal of Medicine*, **2015**, 373, 23-34	59.2	5047
148	Pembrolizumab versus Ipilimumab in Advanced Melanoma. *New England Journal of Medicine*, **2015**, 372, 2521-32	59.2	3792
147	Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma. *New England Journal of Medicine*, **2017**, 377, 1345-1356	59.2	2030
146	Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. *Lancet Oncology, The*, **2015**, 16, 375-84	21.7	1881
145	Combined vemurafenib and cobimetinib in BRAF-mutated melanoma. *New England Journal of Medicine*, **2014**, 371, 1867-76	59.2	1403
144	Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma. *New England Journal of Medicine*, **2019**, 381, 1535-1546	59.2	1260
143	Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma. *New England Journal of Medicine*, **2014**, 371, 1877-88	59.2	1195
142	Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma. *New England Journal of Medicine*, **2017**, 377, 1824-1835	59.2	1178
141	Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma. *New England Journal of Medicine*, **2019**, 380, 1103-1115	59.2	1069
140	Renal cell carcinoma. *Nature Reviews Disease Primers*, **2017**, 3, 17009	51.1	963
139	Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial. *Lancet, The*, **2015**, 386, 444-51	40	926
138	Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma. *New England Journal of Medicine*, **2018**, 378, 1789-1801	59.2	918
137	Genomic architecture and evolution of clear cell renal cell carcinomas defined by multiregion sequencing. *Nature Genetics*, **2014**, 46, 225-233	36.3	866
136	Adjuvant Dabrafenib plus Trametinib in Stage III BRAF-Mutated Melanoma. *New England Journal of Medicine*, **2017**, 377, 1813-1823	59.2	778
135	Safety and efficacy of vemurafenib in BRAF(V600E) and BRAF(V600K) mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study. *Lancet Oncology, The*, **2014**, 15, 323-32	21.7	753

134	Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006). *Lancet, The*, **2017**, 390, 1853-1862	40	703
133	Safety Profile of Nivolumab Monotherapy: A Pooled Analysis of Patients With Advanced Melanoma. *Journal of Clinical Oncology*, **2017**, 35, 785-792	2.2	696
132	Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial. *Lancet Oncology, The* , **2018**, 19, 1480-1492	21.7	680
131	Cobimetinib combined with vemurafenib in advanced BRAF(V600)-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial. *Lancet Oncology, The*, **2016**, 17, 1248-60	21.7	590
130	Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial. *Lancet Oncology, The*, **2015**, 16, 1473-1482	21.7	575
129	Insertion-and-deletion-derived tumour-specific neoantigens and the immunogenic phenotype: a pan-cancer analysis. *Lancet Oncology, The*, **2017**, 18, 1009-1021	21.7	492
128	Intravital imaging reveals how BRAF inhibition generates drug-tolerant microenvironments with high integrin β1/FAK signaling. *Cancer Cell*, **2015**, 27, 574-88	24.3	366
127	Tracking Cancer Evolution Reveals Constrained Routes to Metastases: TRACERx Renal. *Cell*, **2018**, 173, 581-594.e12	56.2	350
126	Efficacy and Safety of Nivolumab Alone or in Combination With Ipilimumab in Patients With Mucosal Melanoma: A Pooled Analysis. *Journal of Clinical Oncology*, **2017**, 35, 226-235	2.2	302
125	Translational implications of tumor heterogeneity. *Clinical Cancer Research*, **2015**, 21, 1258-66	12.9	292
124	Overall Survival in Patients With Advanced Melanoma Who Received Nivolumab Versus Investigator's Choice Chemotherapy in CheckMate 037: A Randomized, Controlled, Open-Label Phase III Trial. *Journal of Clinical Oncology*, **2018**, 36, 383-390	2.2	273
123	Efficacy and Safety Outcomes in Patients With Advanced Melanoma Who Discontinued Treatment With Nivolumab and Ipilimumab Because of Adverse Events: A Pooled Analysis of Randomized Phase II and III Trials. *Journal of Clinical Oncology*, **2017**, 35, 3807-3814	2.2	264
122	Tunable-combinatorial mechanisms of acquired resistance limit the efficacy of BRAF/MEK cotargeting but result in melanoma drug addiction. *Cancer Cell*, **2015**, 27, 240-56	24.3	226
121	Immune checkpoint inhibitors and cardiovascular toxicity. *Lancet Oncology, The*, **2018**, 19, e447-e458	21.7	221
120	Vemurafenib in patients with BRAF(V600) mutated metastatic melanoma: an open-label, multicentre, safety study. *Lancet Oncology, The*, **2014**, 15, 436-44	21.7	206
119	Survival of patients with advanced metastatic melanoma: the impact of novel therapies-update 2017. *European Journal of Cancer*, **2017**, 83, 247-257	7.5	181
118	Efficacy and Safety of Nivolumab in Patients With BRAF V600 Mutant and BRAF Wild-Type Advanced Melanoma: A Pooled Analysis of 4 Clinical Trials. *JAMA Oncology*, **2015**, 1, 433-40	13.4	160
117	Association Between Immune-Related Adverse Events and Recurrence-Free Survival Among Patients With Stage III Melanoma Randomized to Receive Pembrolizumab or Placebo: A Secondary Analysis of a Randomized Clinical Trial. *JAMA Oncology*, **2020**, 6, 519-527	13.4	148

116	Meta-analysis of tumor- and T cell-intrinsic mechanisms of sensitization to checkpoint inhibition. *Cell*, **2021**, 184, 596-614.e14	56.2	144
115	Adjuvant nivolumab versus ipilimumab in resected stage IIIB-C and stage IV melanoma (CheckMate 238): 4-year results from a multicentre, double-blind, randomised, controlled, phase 3 trial. *Lancet Oncology, The*, **2020**, 21, 1465-1477	21.7	140
114	Longer Follow-Up Confirms Relapse-Free Survival Benefit With Adjuvant Dabrafenib Plus Trametinib in Patients With Resected V600-Mutant Stage III Melanoma. *Journal of Clinical Oncology*, **2018**, 36, 3441-3449	2.2	137
113	Survival of patients with advanced metastatic melanoma: The impact of novel therapies. *European Journal of Cancer*, **2016**, 53, 125-34	7.5	115
112	Systematic evaluation of the prognostic impact and intratumour heterogeneity of clear cell renal cell carcinoma biomarkers. *European Urology*, **2014**, 66, 936-48	10.2	109
111	Five-Year Analysis of Adjuvant Dabrafenib plus Trametinib in Stage III Melanoma. *New England Journal of Medicine*, **2020**, 383, 1139-1148	59.2	105
110	Nivolumab for Patients With Advanced Melanoma Treated Beyond Progression: Analysis of 2 Phase 3 Clinical Trials. *JAMA Oncology*, **2017**, 3, 1511-1519	13.4	101
109	Neoadjuvant systemic therapy in melanoma: recommendations of the International Neoadjuvant Melanoma Consortium. *Lancet Oncology, The*, **2019**, 20, e378-e389	21.7	88
108	Independent assessment of lenvatinib plus everolimus in patients with metastatic renal cell carcinoma. *Lancet Oncology, The*, **2016**, 17, e4-5	21.7	86
107	Recurrent chromosomal gains and heterogeneous driver mutations characterise papillary renal cancer evolution. *Nature Communications*, **2015**, 6, 6336	17.4	85
106	Longer Follow-Up Confirms Recurrence-Free Survival Benefit of Adjuvant Pembrolizumab in High-Risk Stage III Melanoma: Updated Results From the EORTC 1325-MG/KEYNOTE-054 Trial. *Journal of Clinical Oncology*, **2020**, 38, 3925-3936	2.2	78
105	Immunotherapy Combined or Sequenced With Targeted Therapy in the Treatment of Solid Tumors: Current Perspectives. *Journal of the National Cancer Institute*, **2016**, 108, djv414	9.7	70
104	Nivolumab versus everolimus in patients with advanced renal cell carcinoma: Updated results with long-term follow-up of the randomized, open-label, phase 3 CheckMate 025 trial. *Cancer*, **2020**, 126, 4156-4167	6.4	66
103	EULAR points to consider for the diagnosis and management of rheumatic immune-related adverse events due to cancer immunotherapy with checkpoint inhibitors. *Annals of the Rheumatic Diseases*, **2021**, 80, 36-48	2.4	61
102	Health-related quality of life impact in a randomised phase III study of the combination of dabrafenib and trametinib versus dabrafenib monotherapy in patients with BRAF V600 metastatic melanoma. *European Journal of Cancer*, **2015**, 51, 833-40	7.5	60
101	Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial. *Lancet Oncology, The*, **2021**, 22, 643-654	21.7	58
100	Health-related quality of life results from the phase III CheckMate 067 study. *European Journal of Cancer*, **2017**, 82, 80-91	7.5	55
99	Genome-wide association study identifies multiple risk loci for renal cell carcinoma. *Nature Communications*, **2017**, 8, 15724	17.4	50

98	Common variation at 2q22.3 (ZEB2) influences the risk of renal cancer. *Human Molecular Genetics*, **2013**, 22, 825-31	5.6	49
97	Adjuvant Vascular Endothelial Growth Factor-targeted Therapy in Renal Cell Carcinoma: A Systematic Review and Pooled Analysis. *European Urology*, **2018**, 74, 611-620	10.2	49
96	Prognostic and predictive value of AJCC-8 staging in the phase III EORTC1325/KEYNOTE-054 trial of pembrolizumab vs placebo in resected high-risk stage III melanoma. *European Journal of Cancer*, **2019**, 116, 148-157	7.5	42
95	Modeled Prognostic Subgroups for Survival and Treatment Outcomes in BRAF V600-Mutated Metastatic Melanoma: Pooled Analysis of 4 Randomized Clinical Trials. *JAMA Oncology*, **2018**, 4, 1382-1388	13.4	42
94	SnapShot: Renal Cell Carcinoma. *Cell*, **2015**, 163, 1556-1556.e1	56.2	41
93	Epigenetic regulation in RCC: opportunities for therapeutic intervention?. *Nature Reviews Urology*, **2012**, 9, 147-55	5.5	41
92	Survival of patients with advanced metastatic melanoma: The impact of MAP kinase pathway inhibition and immune checkpoint inhibition - Update 2019. *European Journal of Cancer*, **2020**, 130, 126-138	7.5	39
91	Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone Versus Ipilimumab in Patients With Advanced Melanoma. *Journal of Clinical Oncology*, **2021**, JCO2102229	2.2	39
90	Prognostic score for patients with advanced melanoma treated with ipilimumab. *European Journal of Cancer*, **2015**, 51, 2785-91	7.5	38
89	Lifileucel, a Tumor-Infiltrating Lymphocyte Therapy, in Metastatic Melanoma. *Journal of Clinical Oncology*, **2021**, 39, 2656-2666	2.2	35
88	Extrinsic factors can mediate resistance to BRAF inhibition in central nervous system melanoma metastases. *Pigment Cell and Melanoma Research*, **2016**, 29, 92-100	4.5	34
87	Gene Expression Profiling in -Mutated Melanoma Reveals Patient Subgroups with Poor Outcomes to Vemurafenib That May Be Overcome by Cobimetinib Plus Vemurafenib. *Clinical Cancer Research*, **2017**, 23, 5238-5245	12.9	30
86	Combination immune checkpoint blockade with ipilimumab and nivolumab in the management of advanced melanoma. *Expert Opinion on Biological Therapy*, **2016**, 16, 389-96	5.4	29
85	Efficacy of PD-1-based immunotherapy after radiologic progression on targeted therapy in stage IV melanoma. *European Journal of Cancer*, **2019**, 116, 207-215	7.5	26
84	Open-Label, Single-Arm Phase II Study of Pembrolizumab Monotherapy as First-Line Therapy in Patients With Advanced Clear Cell Renal Cell Carcinoma. *Journal of Clinical Oncology*, **2021**, 39, 1020-1028	2.2	26
83	Immune Checkpoint Inhibitors for Cancer Therapy in the COVID-19 Era. *Clinical Cancer Research*, **2020**, 26, 4201-4205	12.9	25
82	Adjuvant Sorafenib for Renal Cell Carcinoma at Intermediate or High Risk of Relapse: Results From the SORCE Randomized Phase III Intergroup Trial. *Journal of Clinical Oncology*, **2020**, 38, 4064-4075	2.2	25
81	Genomic Features of Exceptional Response in Vemurafenib Cobimetinib-treated Patients with -mutated Metastatic Melanoma. *Clinical Cancer Research*, **2019**, 25, 3239-3246	12.9	23

80	Eighth American Joint Committee on Cancer (AJCC) melanoma classification: Let us reconsider stage III. *European Journal of Cancer*, **2018**, 91, 168-170	7.5	23
79	Escape from nonsense-mediated decay associates with anti-tumor immunogenicity. *Nature Communications*, **2020**, 11, 3800	17.4	21
78	Representative Sequencing: Unbiased Sampling of Solid Tumor Tissue. *Cell Reports*, **2020**, 31, 107550	10.6	19
77	An immunotherapy survivor population: health-related quality of life and toxicity in patients with metastatic melanoma treated with immune checkpoint inhibitors. *Supportive Care in Cancer*, **2020**, 28, 561-570	3.9	19
76	Five-year outcomes from a phase 3 METRIC study in patients with BRAF V600´E/K-mutant advanced or metastatic melanoma. *European Journal of Cancer*, **2019**, 109, 61-69	7.5	18
75	PACMEL: a phase 1 dose escalation trial of trametinib (GSK1120212) in combination with paclitaxel. *European Journal of Cancer*, **2015**, 51, 359-66	7.5	18
74	Predictive biomarkers for response to immune checkpoint inhibition. *Seminars in Cancer Biology*, **2021**, 79, 4-4	12.7	17
73	Effect of glandular metastases on overall survival of patients with metastatic clear cell renal cell carcinoma in the antiangiogenic therapy era. *Urologic Oncology: Seminars and Original Investigations* , **2016**, 34, 167.e17-23	2.8	15
72	Common variation at 1q24.1 (ALDH9A1) is a potential risk factor for renal cancer. *PLoS ONE*, **2015**, 10, e0122589	3.7	15
71	Determinants of anti-PD-1 response and resistance in clear cell renal cell carcinoma. *Cancer Cell*, **2021**, 39, 1497-1518.e11	24.3	14
70	Optimizing treatment of metastatic renal cell carcinoma by changing mechanism of action. *Expert Review of Anticancer Therapy*, **2011**, 11, 639-49	3.5	13
69	Axitinib for the treatment of metastatic renal cell carcinoma: recommendations for therapy management to optimize outcomes. *American Journal of Clinical Oncology: Cancer Clinical Trials*, **2014**, 37, 397-403	2.7	12
68	Impact of COVID-19 pandemic on treatment patterns in metastatic clear cell renal cell carcinoma. *ESMO Open*, **2020**, 5,	6	12
67	Metastatic chromophobe renal cell carcinoma treated with targeted therapies: A Renal Cross Channel Group´study. *European Journal of Cancer*, **2017**, 80, 55-62	7.5	11
66	BMI and outcomes in melanoma: more evidence for the obesity paradox. *Lancet Oncology, The*, **2018**, 19, 269-270	21.7	11
65	Abstract CT004: Adjuvant therapy with nivolumab (NIVO) combined with ipilimumab (IPI) vs NIVO alone in patients (pts) with resected stage IIIB-D/IV melanoma (CheckMate 915) **2021**,		11
64	TMB and Inflammatory Gene Expression Associated with Clinical Outcomes following Immunotherapy in Advanced Melanoma. *Cancer Immunology Research*, **2021**, 9, 1202-1213	12.5	11
63	Checkpoint inhibitors in advanced melanoma: effect on the field of immunotherapy. *Expert Review of Anticancer Therapy*, **2017**, 17, 647-655	3.5	10

62	Is advanced renal cell carcinoma becoming a chronic disease?. *Lancet, The*, **2010**, 376, 574-5	40	10
61	5-Year Outcomes with Cobimetinib plus Vemurafenib in Mutation-Positive Advanced Melanoma: Extended Follow-up of the coBRIM Study. *Clinical Cancer Research*, **2021**,	12.9	10
60	British Society of Gastroenterology endorsed guidance for the management of immune checkpoint inhibitor-induced enterocolitis. *The Lancet Gastroenterology and Hepatology*, **2020**, 5, 679-697	18.8	9
59	Expanded access programmes: patient interests versus clinical trial integrity. *Lancet Oncology, The*, **2015**, 16, 15-7	21.7	9
58	Bempegaldesleukin plus nivolumab in untreated, unresectable or metastatic melanoma: Phase III PIVOT IO 001 study design. *Future Oncology*, **2020**, 16, 2165-2175	3.6	9
57	Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): health-related quality-of-life results from a double-blind, randomised, controlled, phase 3 trial. *Lancet Oncology, The*, **2021**, 22, 655-664	21.7	9
56	Efficacy of sequential treatment with sunitinib-everolimus in an orthotopic mouse model of renal cell carcinoma. *Anticancer Research*, **2012**, 32, 2399-406	2.3	9
55	RAMPART: A phase III multi-arm multi-stage trial of adjuvant checkpoint inhibitors in patients with resected primary renal cell carcinoma (RCC) at high or intermediate risk of relapse. *Contemporary Clinical Trials*, **2021**, 108, 106482	2.3	8
54	Challenging the treatment paradigm for advanced renal cell carcinoma: a review of systemic and localized therapies. *American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting*, **2015**, e239-47	7.1	7
53	PRISM protocol: a randomised phase II trial of nivolumab in combination with alternatively scheduled ipilimumab in first-line treatment of patients with advanced or metastatic renal cell carcinoma. *BMC Cancer*, **2019**, 19, 1102	4.8	7
52	Malignant Melanoma of the Gastrointestinal Tract: Symptoms, Diagnosis, and Current Treatment Options. *Cells*, **2021**, 10,	7.9	7
51	Activation and transcriptional profile of monocytes and CD8 T cells are altered in checkpoint inhibitor-related hepatitis. *Journal of Hepatology*, **2021**, 75, 177-189	13.4	7
50	The safety of nivolumab for the treatment of metastatic melanoma. *Expert Opinion on Drug Safety*, **2017**, 16, 955-961	4.1	6
49	Immune-checkpoint inhibitors in melanoma and kidney cancer: from sequencing to rational selection. *Therapeutic Advances in Medical Oncology*, **2018**, 10, 1758835918777427	5.4	5
48	Contrast-Enhanced CT Density Predicts Response to Sunitinib Therapy in Metastatic Renal Cell Carcinoma Patients. *Translational Oncology*, **2017**, 10, 679-685	4.9	5
47	Sunitinib in Metastatic Renal Cell Carcinoma: A Systematic Review of UK Real World Data. *Frontiers in Oncology*, **2015**, 5, 195	5.3	5
46	Kidney cancer: Carbonic anhydrase IX in resected clear cell RCC. *Nature Reviews Urology*, **2015**, 12, 309-10	9.5	5
45	Crossover and rechallenge with pembrolizumab in recurrent patients from the EORTC 1325-MG/Keynote-054 phase III trial, pembrolizumab versus placebo after complete resection of high-risk stage III melanoma. *European Journal of Cancer*, **2021**, 158, 156-168	7.5	5

44	Correlative serum biomarker analyses in the phase 2 trial of lenvatinib-plus-everolimus in patients with metastatic renal cell carcinoma. *British Journal of Cancer*, **2021**, 124, 237-246	8.7	5
43	Pembrolizumab in the management of metastatic melanoma. *Melanoma Management*, **2015**, 2, 315-325	2.1	4
42	Lifileucel (LN-144), a cryopreserved autologous tumor infiltrating lymphocyte (TIL) therapy in patients with advanced melanoma: Evaluation of impact of prior anti-PD-1 therapy.. *Journal of Clinical Oncology*, **2021**, 39, 9505-9505	2.2	4
41	Spatial patterns of tumour growth impact clonal diversification in a computational model and the TRACERx Renal study.. *Nature Ecology and Evolution*, **2021**,	12.3	4
40	Lenvatinib for use in combination with everolimus for the treatment of patients with advanced renal cell carcinoma following one prior anti-angiogenic therapy. *Expert Review of Clinical Pharmacology*, **2017**, 10, 251-262	3.8	3
39	The combination of vemurafenib and cobimetinib in advanced melanoma. *Expert Opinion on Orphan Drugs*, **2016**, 4, 1105-1111	1.1	3
38	Systemic anti-cancer therapy (SACT) dataset. *Lancet Oncology, The*, **2014**, 15, 1063	21.7	3
37	Radiological Response Heterogeneity Is of Prognostic Significance in Metastatic Renal Cell Carcinoma Treated with Vascular Endothelial Growth Factor-targeted Therapy. *European Urology Focus*, **2020**, 6, 999-1005	5.1	3
36	The efficacy of immunotherapy for in-transit metastases of melanoma: an analysis of randomized controlled trials. *Melanoma Research*, **2021**, 31, 181-185	3.3	3
35	Relapse models for clear cell renal carcinoma. *Lancet Oncology, The*, **2015**, 16, e376-8	21.7	2
34	Metastatic melanoma: therapeutic agents in preclinical and early clinical development. *Expert Opinion on Investigational Drugs*, **2020**, 29, 739-753	5.9	2
33	Individualising treatment choices in a crowded treatment algorithm. *European Journal of Cancer, Supplement*, **2013**, 11, 160-8	1.6	2
32	Pazopanib-induced alopecia, an underestimated toxicity?. *Frontiers in Oncology*, **2015**, 5, 112	5.3	2
31	Clinical Models to Define Response and Survival With Anti-PD-1 Antibodies Alone or Combined With Ipilimumab in Metastatic Melanoma.. *Journal of Clinical Oncology*, **2022**, JCO2101701	2.2	2
30	A Phase 1 first-in-human trial to evaluate the safety and tolerability of CCT3833, an oral panRAF inhibitor, in patients with advanced solid tumours, including metastatic melanoma.. *Journal of Clinical Oncology*, **2016**, 34, TPS9597-TPS9597	2.2	2
29	Treatment-free survival over extended follow-up of patients with advanced melanoma treated with immune checkpoint inhibitors in CheckMate 067 **2021**, 9,		2
28	PTU-009 Upper gastrointestinal inflammation in patients with immune-checkpoint inhibitor induced diarrhoea **2018**,		2
27	Elevated Levels of Mutant Circulating Tumor DNA and Circulating Hepatocyte Growth Factor Are Associated With Poor Prognosis in Patients With Metastatic Melanoma.. *JCO Precision Oncology*, **2018**, 2, 1-17	3.6	2

26	Effects of Molecular Heterogeneity on Survival of Patients With -Mutated Melanoma Treated With Vemurafenib With or Without Cobimetinib in the coBRIM Study.. *JCO Precision Oncology*, **2018**, 2, 1-18	3.6	2
25	Reply to RComment on EEfficacy and toxicity of treatment with the anti-CTLA-4 antibody ipilimumab in patients with metastatic melanoma after prior anti-PD-1 therapyP. *British Journal of Cancer*, **2017**, 116, e15	8.7	1
24	Reply to E. Hindi and K.R. Hess. *Journal of Clinical Oncology*, **2019**, 37, 1356-1358	2.2	1
23	Atezolizumab, cobimetinib, and vemurafenib as first-line treatment for unresectable metastatic BRAF V600 mutated melanoma.. *Expert Review of Anticancer Therapy*, **2022**, 1-9	3.5	1
22	CAcTUS: A parallel arm, biomarker driven, phase II feasibility trial to determine the role of circulating tumor DNA in guiding a switch between targeted therapy and immune therapy in patients with advanced cutaneous melanoma.. *Journal of Clinical Oncology*, **2021**, 39, TPS9587-TPS9587	2.2	1
21	Association of health-related quality of life (HRQoL) and treatment safety with nivolumab (NIVO) in patients (pts) with resected stage IIIB/C or IV melanoma: Analysis of CheckMate 238 four-year follow-up (FU) data.. *Journal of Clinical Oncology*, **2021**, 39, 9574-9574	2.2	1
20	Analysis of patients (pts) with in-transit metastases treated with nivolumab (NIVO) or ipilimumab (IPI) in CheckMate 238.. *Journal of Clinical Oncology*, **2021**, 39, 9569-9569	2.2	1
19	Endocrinopathies induced by immune checkpoint inhibitors: the need for clear endocrine diagnosis. *Lancet Oncology, The*, **2021**, 22, 905-907	21.7	1
18	Clinical outcomes of patients with corticosteroid refractory immune checkpoint inhibitor-induced enterocolitis treated with infliximab **2021**, 9,		1
17	Severe progressive scarring pembrolizumab-induced lichen planopilaris in a patient with metastatic melanoma. *Australasian Journal of Dermatology*, **2021**, 62, 403-406	1.3	1
16	RAMPART: A model for a regulatory-ready academic-led phase III trial in the adjuvant renal cell carcinoma setting. *Contemporary Clinical Trials*, **2021**, 108, 106481	2.3	1
15	Prospective Cardiovascular Surveillance of Immune Checkpoint Inhibitor-Based Combination Therapy in Patients With Advanced Renal Cell Cancer: Data From the Phase III JAVELIN Renal 101 Trial.. *Journal of Clinical Oncology*, **2022**, JCO2101806	2.2	1
14	Isolated imbalance due to bilateral vestibular failure following immune checkpoint inhibitor administration: two cases. *European Journal of Cancer*, **2021**, 156, 187-189	7.5	0
13	Patient-reported experience of diagnosis, management, and burden of renal cell carcinomas: Results >2,000 patients in 41 countries, with focus on older patients.. *Journal of Clinical Oncology*, **2022**, 40, 306-306	2.2	0
12	External Validation of the 2003 Leibovich Prognostic Score in Patients Randomly Assigned to SORCE, an International Phase III Trial of Adjuvant Sorafenib in Renal Cell Cancer.. *Journal of Clinical Oncology*, **2022**, JCO2101090	2.2	0
11	Prognostic and predictive value of blockers in the EORTC 1325/KEYNOTE-054 phase III trial of pembrolizumab versus placebo in resected high-risk stage III melanoma.. *European Journal of Cancer*, **2022**, 165, 97-112	7.5	0
10	Recent developments in melanoma management. *Trends in Urology & Men's Health*, **2016**, 7, 8-12	0.3	
9	Advances in immunotherapy for melanoma. *Melanoma Management*, **2014**, 1, 19-24	2.1	

8	Advances in the Management of Metastatic Renal Cell Cancer. *European Urology Supplements*, **2009**, 8, 758-761	0.9
7	Reply to E. Hindi. *Journal of Clinical Oncology*, **2021**, 39, 944-946	2.2
6	Integrating peripheral biomarker analyses from JAVELIN Renal 101: Avelumab + axitinib (A + Ax) versus sunitinib (S) in advanced renal cell carcinoma (aRCC).. *Journal of Clinical Oncology*, **2021**, 39, 4547-4547	2.2
5	Patient-reported experience of diagnosis, management, and burden of renal cell carcinomas: Results from the 2020 Global Patient Survey from 41 countries.. *Journal of Clinical Oncology*, **2021**, 39, 4579-4579	2.2
4	Avelumab and axitinib in the treatment of renal cell carcinoma: safety and efficacy. *Expert Review of Anticancer Therapy*, **2020**, 20, 343-354	3.5
3	Reply to T. Olivier et al.. *Journal of Clinical Oncology*, **2022**, JCO2200209	2.2
2	Abstract A012: Advanced melanoma exhibits a diversity of evolutionary routes to lethality. *Cancer Research*, **2022**, 82, A012-A012	10.1
1	Abstract PR002: Advanced melanoma exhibits a diversity of evolutionary routes to lethality. *Cancer Research*, **2022**, 82, PR002-PR002	10.1